People Who Have Had Breast Cancer Cannot Have Estrogen

People Who Have Had Breast Cancer Cannot Have Estrogen


Individuals who have previously had breast cancer should not use estrogen as part of gender-affirming care due to the potential risks associated with hormone-sensitive cancers. Estrogen therapy, a key component of feminizing hormone therapy, can stimulate the growth and proliferation of hormone-sensitive breast cancer cells, which can increase the risk of cancer recurrence or progression. Therefore, individuals with a history of breast cancer are advised against estrogen therapy to prioritize their long-term health and reduce the likelihood of cancer recurrence.
    • Related Articles

    • Navigating Gender-Affirming Care During Cancer Treatment

      Embarking on gender-affirming care while undergoing treatment for cancer presents unique challenges and considerations. This situation requires a delicate balance between respecting personal gender identity goals and addressing the medical ...
    • Gender-Affirming Hormone Treatment and the Risk of Cancer: a Literature Review

      Breast cancer The lifetime risk of breast cancer for cis women is approximately 12%, while the lifetime risk for cis men is approximately 0.1% (Sonnenblick et al., 2018). Research has shown that the lifetime risk of breast cancer for trans women on ...
    • Estrogen cypionate injections – common side effects

      Estrogen cypionate injections, like other forms of estrogen, are used in hormone replacement therapy for transgender women (assigned male at birth) as part of gender-affirming care to feminise secondary sexual characteristics. Here are potential ...
    • Estrogen cypionate injections – common side effects

      Estrogen cypionate injections, like other forms of estrogen, are used in hormone replacement therapy for transgender women (assigned male at birth) as part of gender-affirming care to feminise secondary sexual characteristics. Here are potential ...
    • People Who Have Prostate Cancer Cannot Have Testosterone

      Individuals with prostate cancer are typically advised against testosterone therapy as part of gender affirming care due to potential risks associated with hormone-sensitive tumors. Testosterone, a primary component of masculinizing hormone therapy, ...